Related Experiment Video
Updated: Sep 13, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Interplay of rheumatoid arthritis and cardiovascular disease: Insights and prospects
Anastasia V Poznyak1, Nikolay A Orekhov2, Alexey V Churov2,3
1Institute for Atherosclerosis Research, Moscow, Russia.
Insights
Rheumatoid arthritis (RA) patients face higher cardiovascular disease (CVD) risk from chronic inflammation. Standard risk assessments often underestimate this, necessitating personalized strategies for better patient outcomes.
Area of Science:
- Rheumatology
- Cardiology
- Immunology
Background:
- Rheumatoid arthritis (RA) is a chronic inflammatory condition.
- RA significantly elevates the risk of cardiovascular disease (CVD).
- Systemic inflammation in RA is a key driver of CVD.
Purpose of the Study:
- To critically analyze the relationship between RA and CVD.
- To elucidate mechanisms linking RA inflammation to cardiovascular risk.
- To evaluate current treatment strategies for mitigating CVD in RA patients.
Main Methods:
- Systematic literature review.
- Evaluation of conventional CVD risk factors in RA.
- Analysis of inflammation-specific markers impacting cardiovascular outcomes.
Main Results:
- Chronic inflammation in RA substantially increases CVD risk.
- Standard CVD risk assessment protocols often underestimate risk in RA patients.
- Disease-modifying antirheumatic drugs (DMARDs) like methotrexate may reduce CVD risk.
Conclusions:
- Current CVD risk assessment in RA is often inadequate.
- Integrating novel risk factors and personalized management is crucial.
- Improved understanding and tailored strategies can enhance outcomes for RA patients at high CVD risk.
Abstract:
Rheumatoid arthritis significantly increases the risk of cardiovascular disease due to chronic inflammation. This review's purpose is to critically analyze the intricate relationship between rheumatoid arthritis and cardiovascular disease, highlighting the mechanisms by which systemic inflammation contributes to cardiovascular risk and the effectiveness of current treatment strategies. We systematically evaluate existing literature on conventional cardiovascular risk factors in rheumatoid arthritis patients, as well as inflammation-specific markers that influence cardiovascular outcomes. Our conclusions indicate that while several treatment modalities, including methotrexate and other disease-modifying agents, may mitigate cardiovascular risk, there is a prevalent underestimation of true risk by standard cardiovascular disease assessment protocols. This review provides unique contributions by emphasizing the importance of integrating novel risk factors into assessment protocols and advocating for personalized management strategies that cater to the specific needs of rheumatoid arthritis patients. By synthesizing these elements, we aim to enhance understanding and guide clinicians in improving outcomes for rheumatoid arthritis patients at heightened risk of cardiovascular complications.
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease IV: Nursing Management
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Pericarditis I: Introduction

